Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan versus sildenafil for persistent pulmonary hypertension of the newborn
IRCT20190127042504N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bosentan and sildenafil in persistent pulmonary hypertension of the newborn (PPHN) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Pulmonary artery pressure. Started Jun 2017; status: completed.
02
Drugs
bosentansildenafil
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on IRCT20190127042504N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190127042504N1.